{"product_id":"goodrx-pestle-analysis","title":"GoodRx PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political, economic, social, technological, legal, and environmental forces are reshaping GoodRx’s strategy and margins in our concise PESTLE Analysis. Packed with actionable insights for investors and strategists, it pinpoints risks and growth levers. Purchase the full report to get the complete, editable breakdown and make smarter decisions today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing reform momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS and state policymakers continue targeting high prescription costs, reshaping discount and rebate flows. GoodRx could benefit from expanded transparency mandates, but tighter rebate controls risk margin compression. The Inflation Reduction Act set Medicare drug negotiation to start with 10 drugs announced Aug 2023 for 2026, and broader negotiation\/reference pricing could shift the listed prices GoodRx aggregates. Ongoing 2024–25 congressional hearings keep pricing in the political spotlight, driving pharmacy and PBM volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBM transparency and regulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeightened scrutiny of PBMs — where the top three manage roughly 80% of US prescriptions — is pushing for clearer pass-through of rebates and fee structures, with rebates often exceeding 20% on branded drugs. This could force renegotiation of pharmacy network contracts that underpin GoodRx coupons and alter consumer price dynamics. If spread pricing is curtailed, net savings to consumers and retail partners may compress. GoodRx must adapt to evolving PBM reporting and contracting practices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth policy continuity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTemporary telehealth flexibilities tied to the public health emergency (ended May 11, 2023) remain in phased transition, creating uncertain continuity for GoodRx telehealth services. Federal and state choices on cross-state practice — the Interstate Medical Licensure Compact covered 39 jurisdictions by 2024 — and prescribing rules directly shape platform usage. Reimbursement parity, present in roughly 23 states in 2024, affects provider supply and patient adoption. Policy rollbacks could raise friction and materially reduce utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare coverage expansions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedicaid redeterminations eliminated roughly 15 million enrollees during 2023–24, while ACA marketplace enrollment topped 16 million in 2024, shifting out-of-pocket demand for discounts. Expanded coverage typically reduces coupon reliance, but coverage losses drove spikes in GoodRx use; subsidy policy swings can rapidly change user volumes. GoodRx must tailor offers to payer coverage gaps and redetermination timing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicaid losses ≈ 15M (2023–24)\u003c\/li\u003e\n\u003cli\u003eACA enrollees \u0026gt;16M (2024)\u003c\/li\u003e\n\u003cli\u003eCoverage loss → higher coupon use\u003c\/li\u003e\n\u003cli\u003eSubsidy shifts → rapid volume swings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition policy and consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical resistance to healthcare consolidation is intensifying and shapes pharmacy, PBM and telehealth M\u0026amp;A; tighter antitrust scrutiny—with the top three PBMs controlling roughly 80% of US prescription claims as of 2024—could slow rival integration and preserve GoodRx’s competitive position, while payer or pharmacy vertical integration could marginalize third-party platforms and erode GoodRx’s access and pricing leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePBM concentration ~80% (top 3) in 2024\u003c\/li\u003e\n\u003cli\u003eUS retail prescriptions ~4.5 billion annually\u003c\/li\u003e\n\u003cli\u003eAntitrust enforcement rising—risks to rival M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003ePolicy shifts directly affect GoodRx bargaining power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing reforms, Medicare 2026 negotiations and PBM dominance heighten margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUS\/state actions on drug pricing and rebate transparency (IRA Medicare negotiations starting 2026) heighten regulatory risk and could compress GoodRx margins. PBM scrutiny—top three PBMs ~80% share in 2024—threatens network\/rebate structures that underpin coupon economics. Coverage shifts (Medicaid −≈15M 2023–24; ACA enrollees \u0026gt;16M 2024) drive rapid demand swings for discounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid losses\u003c\/td\u003e\n\u003ctd\u003e≈15M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eACA enrollment\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;16M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 PBM share\u003c\/td\u003e\n\u003ctd\u003e≈80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS annual scripts\u003c\/td\u003e\n\u003ctd\u003e≈4.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003e10 drugs announced (Aug 2023) for 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect GoodRx across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and examples specific to the U.S. prescription discount and telehealth market. Designed for executives and investors, it highlights risks, opportunities, and forward-looking insights ready for inclusion in strategy documents and pitch materials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, PESTLE-segmented summary that highlights regulatory, economic, technological and competitive risks and opportunities for GoodRx, designed for quick sharing in presentations or team alignment to guide risk mitigation and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer out-of-pocket pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh inflation in everyday goods (U.S. CPI ~3.0% in 2024) amplifies sensitivity to drug prices, driving higher coupon use. Rising HDHP enrollment (about 31% of covered workers in 2024 per KFF) and larger deductibles increase price shopping for prescriptions. Recessionary strains in 2023–24 elevated discount-seeking, strengthening GoodRx’s budget-focused value proposition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy margin dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacy reimbursement and DIR fee shifts have tightened margins and reduce willingness to honor third-party discounts, pressuring network participation.\u003c\/p\u003e\n\u003cp\u003eIf margins compress, chains may limit GoodRx acceptance or steer patients to in-house savings, while independents—about 21,000 U.S. stores—may lean on GoodRx to drive foot traffic.\u003c\/p\u003e\n\u003cp\u003eGoodRx’s network spans over 70,000 pharmacies, so reimbursement cycles materially affect its breadth and economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvertising and CAC volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital ad pricing and signal loss have pushed industry CPA estimates as much as 20% higher, increasing GoodRx’s customer acquisition costs and making paid performance channels more volatile. Economic slowdowns can lower CPMs but sharpen competition for clicks and conversions. Strong retention, SEO and organic pharmacy referrals reduce paid-channel dependence. Maintaining strict CAC discipline is critical to preserve GoodRx’s unit economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric vs brand mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenerics drive the bulk of GoodRx coupon volume, reflecting that nearly 90% of U.S. prescriptions are generics (FDA), yielding sizable relative savings versus brands. Brand price inflation can boost reported headline savings but faces tighter overlap with manufacturer copay and rebate programs. Patent cliffs and rising biosimilar approvals (over 40 FDA approvals through 2024) shift category economics and competitive mix, altering revenue and margin per fill.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics share: nearly 90% of dispensed prescriptions (FDA)\u003c\/li\u003e\n\u003cli\u003eBrand inflation: raises headline savings but competes with manufacturer programs\u003c\/li\u003e\n\u003cli\u003eBiosimilars: 40+ FDA approvals through 2024, changing biologic economics\u003c\/li\u003e\n\u003cli\u003eMix impact: shifts revenue and margin per fill\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth monetization elasticity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsumer willingness to pay for virtual visits varies with income, copays, and employer benefits; US median household income was about 74,580 in 2023, and telehealth stabilized at roughly 5–10% of outpatient visits post‑pandemic, so price sensitivity is high among lower‑income cohorts. Price points must match perceived convenience and access; bundling telehealth with medication savings historically raises conversion and retention for platforms like GoodRx. Macro cycles—employment, disposable income, and insurance coverage—shift cash‑pay telehealth demand noticeably across economic expansions and downturns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIncome sensitivity: median HH income 74,580 (2023)\u003c\/li\u003e\n\u003cli\u003eTelehealth share: ~5–10% of visits post‑pandemic\u003c\/li\u003e\n\u003cli\u003eBundling boosts conversion: proven in integrated Rx+telehealth models\u003c\/li\u003e\n\u003cli\u003eMacro impact: demand rises in expansions, falls in downturns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing reforms, Medicare 2026 negotiations and PBM dominance heighten margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh 2024 inflation (U.S. CPI ~3.0%) and 31% HDHP penetration drive price‑sensitive coupon use; GoodRx’s 70,000‑pharmacy network and 21,000 independents amplify both risk and opportunity. Margin pressure from DIR\/reimbursement shifts and ~20% higher digital CPA raise CAC, while generics (~90% of fills) and 40+ biosimilar approvals through 2024 reshape fill economics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. CPI (2024)\u003c\/td\u003e\n\u003ctd\u003e~3.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDHP enrollment (2024)\u003c\/td\u003e\n\u003ctd\u003e~31%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies in network\u003c\/td\u003e\n\u003ctd\u003e~70,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndependent pharmacies\u003c\/td\u003e\n\u003ctd\u003e~21,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar approvals (through 2024)\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital CPA change\u003c\/td\u003e\n\u003ctd\u003e~+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGoodRx PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact GoodRx PESTLE Analysis you’ll receive after purchase—fully formatted and ready to use. This screenshot reflects the final content, layout, and structure with no placeholders. After checkout you’ll instantly download this exact file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162687091065,"sku":"goodrx-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/goodrx-pestle-analysis.png?v=1762706664","url":"https:\/\/portersfiveforce.com\/products\/goodrx-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}